Fusion Antibodies (LON:FAB) Shares Down 3.4% – Here’s What Happened

Shares of Fusion Antibodies plc (LON:FAB) were down 3.4% during mid-day trading on Thursday . The stock traded as low as GBX 6.21 ($0.08) and last traded at GBX 6.65 ($0.09). Approximately 345,364 shares traded hands during trading, a decline of 66% from the average daily volume of 1,010,121 shares. The stock had previously closed at GBX 6.88 ($0.09).

Fusion Antibodies Stock Down 3.4%

The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The firm has a fifty day simple moving average of GBX 6.66 and a 200-day simple moving average of GBX 7.22. The company has a market capitalization of £6.25 million, a PE ratio of -1.49 and a beta of 0.49.

Insider Activity

In other news, insider Adrian Kinkaid purchased 100,000 shares of the stock in a transaction dated Tuesday, May 6th. The stock was acquired at an average cost of GBX 6 ($0.08) per share, for a total transaction of £6,000 ($8,079.72). Company insiders own 11.39% of the company’s stock.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.